Search

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more

Sponsor opportunities

The European Hematology Association (EHA) invites you to support the EHA Research Conference 2025, titled "Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis" 

This meeting enables the industry to network with delegates, demonstrate their products and present their latest material…

Read more

Sponsor Opportunities

The European Hematology Association (EHA) invites you to support the 7th European CAR T-cell Meeting.

Read more

SWG Preceptorship Program

Funding to enable an SWG create its own preceptorship—and promote learning and innovation in our community. The call for proposals closed at 12:00 CEST on March 28, 2025.

Read more

Gdf -11 a new target to improve anemia in thalassemia.

 

β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.

Read more

Expert opinions for COVID-19 vaccination in patients with non-malignant hematologic diseases

Carlo Dufour, Helen Papadaki, Alan Warren, Colm Bradley, Cristina Mecucci, Jan Palmblad, Cornelia Zeidler, Francesca Fioredda, Sam Salek, Brigitte  Schlegelberger and Daniela Guardo, on behalf of the EHA SWG on Granulocytes and Constitutional Marrow Failure Disorders; Carlo L.

Read more

Privacy statement

May 21, 2021

Privacy Statement European Hematology Association

Personal Data is processed in the context of the services provided by European Hematology Association (hereinafter also; “EHA”).

Read more